Remission From Stage D Heart Failure (RESTAGE-HF)
Remission From Stage D Heart Failure (RESTAGE-HF)
Sponsor: Thoratec Corporation
This PHASE4 trial investigates Heart Failure NYHA Class III and Heart Failure NYHA Class IV and is currently ongoing. Thoratec Corporation leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
May 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Phase: NA → PHASE4
-
Jan 2017 — May 2017 [monthly]
Recruiting NA
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Thoratec Corporation
- University of Louisville
For direct contact, visit the study record on ClinicalTrials.gov .